Read the latest reports on Western Europe, with local insight, sp...
Read the latest reports on Western Europe, with local insight, specialist knowledge and a comprehensive breakdown of key market data. Our research identifies key strategic themes relevant across the region, while also providing a more granular unders...
Cough remedies and decongestants, which had seen strong growth during the pandemic period, saw more moderate growth in 2022 and 2023 as the contagion receded and public concern waned. Current value sales growth partly reflects inflationary pressures,…
Within OTC consumer health in France, value sales of cough, cold and allergy (hay fever) remedies are continuing to record the fastest growth in 2023, following a dynamic performance the previous year. Within the category, demand for various formats…
In May 2022, Greece lifted all COVID-19 related regulations. This included the compulsory use of face masks and social distancing rules, and although use of face masks remains fairly high in Greece compared to other European countries, it appears…
Cough, cold and allergy (hay fever) remedies are enjoying strong growth in 2023 as the category continues to recover from the sharp declines seen during the COVID-19 pandemic. Flu, common coughs and colds and seasonal allergies in the Irish…
Cough/cold remedies are set to see high single-digit growth in current value terms in 2023, with sales likely to benefit from a high number of cases of cold and flu in the 2023/2024 season. Furthermore, value sales will likely also be boosted by unit…
Cough, cold and allergy (hay fever) remedies remains the largest OTC category in Norway, accounting for more than one-third of total OTC value sales in 2023. Despite the already relatively high penetration of these products, the category registered…
Cough, cold, and allergy (hay fever) remedies is projected to continue to post retail current value growth in 2023, following a severe decline in 2020 due to the Coronavirus (COVID-19) pandemic. Having passed the 2019 pre-pandemic level in 2022, the…
Sales of dermatologicals strongly rely on consumers visiting pharmacies (the dominant distribution channel) as Belgians rarely go first to these stores specifically to purchase such products. Instead these are generally secondary purchases alongside…
Dermatologicals is expected to register an increase in current value sales in 2023, partly as a result of the energy crisis stemming from the war in Ukraine, which is pushing up retail prices.
Value growth for dermatologicals continues to slow in 2023 as local consumers prioritise the treatment of other health concerns. According to a study led by the French Society of Dermatology (SFD), one in three French citizen suffers from a skin…